Proton Partners International has partnered with humediQ GmbH to achieve its goal of creating centres of excellence for advanced cancer treatment in the UK and beyond by providing the latest, most advanced technology in radiotherapy patient monitoring.
Proton Partners International will operate three oncology centers in the UK over the next two years. In addition to proton therapy, the centers will offer radiotherapy and chemotherapy to treat, private patients under medical insurance and self-pay patients and NHS patients.
Proton Partners will acquire humediQ’s IDENTIFY SURFACE patient positioning and motion management system, the most modern solution on the market, for both its conventional and proton therapy systems.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Mike Moran, Chief Executive Officer of Proton Partners International, says: “We are committed to providing the highest quality of treatment at our centers and as such we are working with world class-leading partners. We are pleased to be working in partnership with humediQ, which is renowned for the innovation and excellence of its products and services.”
Christian Hieronimi, Chief Executive Officer at humediQ GmbH, says:
“We are very pleased to support Proton Partners in transforming care in the UK and beyond. humediQ’s comprehensive patient positioning and monitoring solutions are designed to ensure patient safety while being treated with highly accurate forms of radiation therapy. Its ease of use will play a vital role in helping Proton Partners to achieve their goal of treating more than 2,000 patients annually.”
According to Cancer Research UK, the number of new cancer cases each year in the UK is expected to reach around 432,000 by 2030, and half of these patients should receive radiotherapy at some point in their treatment.
Patient safety has to be at the forefront of any radiotherapy service and with the projected increase in patient volumes, combined with the evolution of more precise hypo-fractionated treatments, accurate patient positioning and motion management will be crucial to take full advantage of these new treatment regimes.
Stewart Pegrum, humediQ’s Vice President EMEA, adds: “Proton Partners and humediQ are committed to bring the best, safest and most innovative radiotherapy solutions to cancer patients in the UK and beyond.”
